zacks.com · 2 jul

NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population

Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.

marketbeat.com · 1 jul

3 European Stocks to Carry Investors Through the Back Half of 2026

The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story:

gurufocus.com · 25 jun

Novartis Eyes $5 Billion Pluvicto Opportunity

Novartis (NVS) is sitting at the center of a fast-growing oncology market as radioligand therapy gains momentum in cancer treatment. The therapy uses targeted r

reuters.com · 24 jun

Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis

Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth ​up to about $1.9 billion, aiming to develop therapies ‌for historically hard-to-drug cancer targets.

businesswire.com · 24 jun

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop and commercialize small molecule therapies against promising but historically undruggable oncology targets. The agreement underscores the productivity and breadth of Antares' discovery capabilities, which have repeatedly delivered development candi.

zacks.com · 23 jun

Biotech's Silent Resurgence (5-Year Base Breakout)

The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.

zacks.com · 15 jun

Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study

Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.

247wallst.com · 13 jun

Dividend Safety Check: FNDF and International Large-Cap Dividend Income

The Schwab Fundamental International Equity ETF (NYSEARCA:FNDF) pays semi-annual distributions sourced from a basket of developed-market dividend payers outside the United States, and at roughly $54 a share the fund has quietly become a core income holding for investors who want global diversification without chasing yield.